LSL Pharma Seals Two Agreements to Market New Ophthalmic Products in Canada

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

LSL Pharma Seals Two Agreements to Market New Ophthalmic Products in Canada

, MT Newswires - 7:55 AM ET 4/3/2025 default

07:55 AM EDT, 04/03/2025 (MT Newswires) -- LSL Pharma Group (LSL.V) on Thursday said it has signed two agreements to market six to 10 sterile eye drops for the prescription market in Canada.

Four of the new products will be exclusive to the company for the Canadian market, with no generic equivalent. The commercialization of the new products remains subject to due diligence by LSL and to regulatory approvals.

"We are extremely pleased to have signed these two commercial agreements for new prescription ophthalmic products. These products will significantly enhance the ophthalmic portfolio of our Steri-Med Pharma division," said Francois Roberge, chief executive officer. "The company expects to start commercialization of some of these products as early as the fourth quarter of 2025. Together, these products represent an annual market of over $105 million in Canada, according to IQVIA Canada data."

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.